SCHEMBL7184400

SCHEMBL7184400

COc1cccc(OC)c1C(=O)P(=O)(C(=O)c1c(C)cc(C(C)(C)C)cc1C)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
NR1H4 Q96RI1 3/20 0.38
MAPT P10636 2/20 0.38
TAAR1 Q96RJ0 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
LMNA P02545 2/20 0.37
KDM4E B2RXH2 1/20 0.37
ALDH1A1 P00352 1/20 0.37
HTT P42858 2/20 0.36
NPC1 O15118 1/20 0.36
MAPK1 P28482 1/20 0.36
STAT1 P42224 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7188953 0.92 FABP4 (0.38) CA12CA1CA2CA7CA9
SCHEMBL7190322 0.91 NR1H4 (0.37) NR1H4MAPTNPSR1LMNAKDM4E
SCHEMBL7178020 0.90 KMT2A (0.39) NR1H4MAPTATMNPSR1LMNA
SCHEMBL7190262 0.89 MAPT (0.39) CA12CA1CA2CA7CA9
SCHEMBL7185487 0.89 CA12 (0.41) CA12CA1CA2CA7CA9
SCHEMBL5043180 0.88 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL7187514 0.88 LMNA (0.40) NR1H4MAPTNPSR1LMNAALDH1A1
SCHEMBL7183691 0.87 RXFP1 (0.42) MAPTALDH1A1RAB9ASMN1; SMN2TSHR
SCHEMBL7182360 0.87 TP53 (0.39) NR1H4MAPTNPSR1LMNAALDH1A1
SCHEMBL7177382 0.87 CA12 (0.49) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 CA12 1552/4885CA1 2219/4885CA2 2297/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 CA12 1320/4885CA1 2302/4885CA2 2346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.